Macitentan in Pulmonary Arterial Hypertension Due to Congenital Heart Disease (CHD-PAH): Real-World Evidence from the OPUS/OrPHeUS Studies

By sjmartinez • November 26, 2024

Chin KM, Channick R, Kim NH, Ong R, Turricchia S, Martin N, Mitchell L, McLaughlin VV. Macitentan in Pulmonary Arterial Hypertension Due to Congenital Heart Disease (CHD-PAH): Real-World Evidence from the OPUS/OrPHeUS Studies. Cardiol Ther. 2024 Nov 25. doi: 10.1007/s40119-024-00386-1. Epub ahead of print. PMID: 39585521.

Tags: congenital heart disease, Macitentan, Publications, pulmonary arterial hypertension, Pulmonary, Critical Care & Sleep Medicine, real-world evidence

Earlier initiation of tenofovir in pregnancy with infant hepatitis B vaccination obviates the need for hepatitis B immune globulin

Pak K, Saab S. Earlier initiation of tenofovir in pregnancy with infant hepatitis B vaccination obviates the need for hepatitis B immune globulin. Transl Gastroenterol[...]

Intravitreal vascular endothelial growth factor inhibitor systemic and renal toxicity registry

Nguyen MD, Fekrat R, Gee C, Demirci AN, Kharabaf S, Le D, Tadros M, Nguyen VQ, Patel S, Truong T, Ahdoot R, Kurtz IB, Kerr[...]

Insurance companies’ lack of LGBTQ+ affirmation: discrimination, distrust, and dissatisfaction among LGBTQ+ people

Nowaskie DZ, Blackwood D, Garcia F, Flautero JD. Insurance companies' lack of LGBTQ+ affirmation: discrimination, distrust, and dissatisfaction among LGBTQ+ people. Front Sociol. 2025 Jul[...]